Sort
82,697 grants matching “vaccine development”
CCR Genomics Core
$1,245,898Elizabeth Conner · Division Of Basic Sciences - Nci · ZIC · FY2016 · CA
Enhancing B cell immunity against HIV-1 using novel vaccine delivery platforms
$1,245,610Michael W Cho · Iowa State University · U19 · FY2012 · AI
Structure and immunogenicity of novel trimeric HIV-1 Env immunogens
$1,245,461Xiangpeng Kong · New York University School Of Medicine · R01 · FY2023 · AI
Project 4: PK-PD of a Combination Antiretroviral Intravaginal Ring in Women
$1,245,113Kathleen Listiak Vincent · Oak Crest Institute Of Science · U19 · FY2018 · AI
Immune Function and Biodefense in Children, Elderly, and Immunocrompromised
$1,245,000Icahn School Of Medicine At Mount Sinai · N01 · FY2009 · AI
Regulation of Cutaneous Accessory Cell Activity in Health and Disease
$1,244,611Mark Udey · Clinical Sciences · Z01 · FY2007 · CA
Advanced Development of Vaccines for Antibiotic Resistant Bacteria
$1,244,544Frank Malinowski · Eveliqure Biotechnologies, Gmbh · N01 · FY2021 · AI
Partnership to Assess Viral and Immune Landscape Intersections with ONcology for People Living with HIV (PAVILION)
$1,244,501Anna R Giuliano · H. Lee Moffitt Cancer Ctr & Res Inst · U54 · FY2023 · CA
Development of broad nanovaccines targeting diverse coronavirus receptor-binding sites
$1,244,471Daniel Kulp · Wistar Institute · P01 · FY2022 · AI
Vaccine and Treatment Evaluation Units
$1,244,414Nadine Georges Rouphael · Emory University · UM1 · FY2023 · AI
A Novel Systemic and Mucosal Adjuvant for Biodefense
$1,244,356Robert E. Johnston · Global Vaccines, Inc. · U01 · FY2006 · AI
Preclinical Studies and Mucosal Responses
$1,244,087Rama Rao Amara · Geovax, Inc. · U19 · FY2009 · AI
Immune correlates of protection
$1,243,986Richard A Koup · National Institute Of Allergy And Infectious Diseases · ZIA · FY2023 · AI
CTSA INFRASTRUCTURE FOR AIDS RESEARCH
$1,243,730Barry Coller · Rockefeller University · UL1 · FY2010 · RR
CTSA INFRASTRUCTURE FOR AIDS RESEARCH
$1,243,729Barry Coller · Rockefeller University · UL1 · FY2010 · RR
Expanding the breadth, magnitude, and durability of PfSPZ vaccines by creating multi-strain vaccines, designer hybrid and genetically altered parasite vaccines and use of a unique adjuvant.
$1,243,700B. Kim Lee Sim · Sanaria, Inc. · U01 · FY2023 · AI
Comparative Modeling to Inform Cervical Cancer Control Policies
$1,243,668Jane Jooyun Kim · Harvard School Of Public Health · U01 · FY2022 · CA
Sample Collection and General Screening Protocols
$1,243,646Lesia Dropulic · National Institute Of Allergy And Infectious Diseases · ZIA · FY2022 · AI
Task A47: Development of Ferret and Hamster Reagents for Immunological Studies
$1,243,577Saul Tzipori · Tufts University Boston · N01 · FY2020 · AI
Non-Human Primate Core
$1,243,332Norman L Letvin · Duke University · U19 · FY2010 · AI
University of Rochester Vaccine and Treatment Evaluation Unit(VTEU)-DMID 21-0012
$1,242,949Ann R Falsey · University Of Rochester · UM1 · FY2021 · AI
Innate inflammatory responses during pulmonary infections
$1,242,800Katrin Mayer-Barber · National Institute Of Allergy And Infectious Diseases · ZIA · FY2021 · AI
Yerkes National Primate Research Center Role of type-I IFN in regulating COVID-19 induced inflammation and pathogenesis
$1,242,793Jonathan S Lewin · Emory University · P51 · FY2021 · OD
CENTER FOR DEVELOPMENT OF ANTISPERM CONTRACEPTIVES
$1,242,592University Of California Davis · U54 · FY2001 · HD
Therapeutic Approaches for Prion Disease
$1,242,287Thomas M Wisniewski · New York University School Of Medicine · R01 · FY2009 · NS